{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:27:51Z","timestamp":1781306871455,"version":"3.54.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fay Fuller Foundation","award":["no funding number given"],"award-info":[{"award-number":["no funding number given"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2829-7","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T13:58:39Z","timestamp":1534773519000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo"],"prefix":"10.1186","volume":"19","author":[{"given":"C\u00e9lia","family":"Fourrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie T.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard T.","family":"Baune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"issue":"20","key":"2829_CR1","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1056\/NEJM200005183422001","volume":"342","author":"MB Keller","year":"2000","unstructured":"Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000;342(20):1462\u201370.","journal-title":"N Engl J Med"},{"key":"2829_CR2","doi-asserted-by":"crossref","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28\u201340.","DOI":"10.1176\/appi.ajp.163.1.28"},{"key":"2829_CR3","doi-asserted-by":"crossref","unstructured":"Anthony DC, Couch Y, Losey P et al. The systemic response to brain injury and disease. Brain Behav Immun. 2012;26(4):534\u201340.","DOI":"10.1016\/j.bbi.2011.10.011"},{"issue":"2","key":"2829_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.pharmthera.2011.01.014","volume":"130","author":"L Capuron","year":"2011","unstructured":"Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130(2):226\u201338.","journal-title":"Pharmacol Ther"},{"key":"2829_CR5","doi-asserted-by":"crossref","unstructured":"Louveau A, Smirnov I, Keyes TJ et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337\u201341.","DOI":"10.1038\/nature14432"},{"issue":"2","key":"2829_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.iac.2009.02.002","volume":"29","author":"R Dantzer","year":"2009","unstructured":"Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin N Am. 2009;29(2):247\u201364.","journal-title":"Immunol Allergy Clin N Am"},{"issue":"2","key":"2829_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bbi.2006.09.006","volume":"21","author":"R Dantzer","year":"2007","unstructured":"Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun. 2007;21(2):153\u201360.","journal-title":"Brain Behav Immun"},{"key":"2829_CR8","doi-asserted-by":"crossref","unstructured":"Kelley KW, Bluthe RM, Dantzer R et al. Cytokine-induced sickness behavior. Brain Behav Immun. 2003;17(Suppl 1):S112\u20138.","DOI":"10.1016\/S0889-1591(02)00077-6"},{"issue":"1","key":"2829_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.it.2005.11.006","volume":"27","author":"CL Raison","year":"2006","unstructured":"Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24\u201331.","journal-title":"Trends Immunol"},{"key":"2829_CR10","doi-asserted-by":"crossref","unstructured":"Eggermont AMM, Suciu S, Santinami M et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633):117\u201326.","DOI":"10.1016\/S0140-6736(08)61033-8"},{"key":"2829_CR11","unstructured":"Friebe A, Horn M, Schmidt F et al. Dose-dependent development of depressive symptoms during adjuvant interferon-alpha treatment of patients with malignant melanoma. Psychosomatics. 2010;51(6):466\u201373."},{"key":"2829_CR12","doi-asserted-by":"publisher","first-page":"S174","DOI":"10.1097\/01.aids.0000192087.64432.ae","volume":"19","author":"A Reichenberg","year":"2005","unstructured":"Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS. 2005;19:S174\u20138.","journal-title":"AIDS"},{"issue":"11","key":"2829_CR13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.biopsych.2004.02.009","volume":"56","author":"L Capuron","year":"2004","unstructured":"Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry. 2004;56(11):819\u201324.","journal-title":"Biol Psychiatry"},{"key":"2829_CR14","doi-asserted-by":"crossref","unstructured":"Raison CL, Demetrashvili M, Capuron L et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19(2):105\u201323.","DOI":"10.2165\/00023210-200519020-00002"},{"key":"2829_CR15","doi-asserted-by":"crossref","unstructured":"Baraldi S, Hepgul N, Mondelli V et al. Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol. 2012;32(4):531\u201343.","DOI":"10.1097\/JCP.0b013e31825d9982"},{"key":"2829_CR16","doi-asserted-by":"crossref","unstructured":"Hou XJ, Xu JH, Wang J et al. Can antidepressants prevent pegylated interferon-alpha\/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials? PLoS One. 2013;8(10):e76799.","DOI":"10.1371\/journal.pone.0076799"},{"key":"2829_CR17","doi-asserted-by":"crossref","unstructured":"Benros ME, Waltoft BL, Nordentoft M et al. Autoimmune diseases and severe infections as risk factors for mood disorders a Nationwide study. JAMA Psychiatry. 2013;70(8):812\u201320.","DOI":"10.1001\/jamapsychiatry.2013.1111"},{"key":"2829_CR18","doi-asserted-by":"crossref","unstructured":"Dickens C, McGowan L, Clark-Carter D et al. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med. 2002;64(1):52\u201360.","DOI":"10.1097\/00006842-200201000-00008"},{"key":"2829_CR19","doi-asserted-by":"crossref","unstructured":"Korczak DJ, Pereira S, Koulajian K et al. Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link. Diabetologia. 2011;54(10):2483\u201393.","DOI":"10.1007\/s00125-011-2240-3"},{"key":"2829_CR20","doi-asserted-by":"crossref","unstructured":"Wium-Andersen MK, Orsted DD, Nielsen SF et al. Elevated C-reactive protein levels, psychological distress, and depression in 73131 individuals. JAMA Psychiatry. 2013;70(2):176\u201384.","DOI":"10.1001\/2013.jamapsychiatry.102"},{"key":"2829_CR21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fendo.2014.00074","volume":"5","author":"N Castanon","year":"2014","unstructured":"Castanon N, Lasselin J, Capuron L. Neuropsychiatric comorbidity in obesity: role of inflammatory processes. Front Endocrinol (Lausanne). 2014;5:74.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2829_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fnins.2015.00229","volume":"9","author":"N Castanon","year":"2015","unstructured":"Castanon N, Luheshi G, Laye S. Role of neuroinflammation in the emotional and cognitive alterations displayed by animal models of obesity. Front Neurosci. 2015;9:229.","journal-title":"Front Neurosci"},{"key":"2829_CR23","doi-asserted-by":"crossref","unstructured":"Dowlati Y, Herrman N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446\u201357.","DOI":"10.1016\/j.biopsych.2009.09.033"},{"issue":"12","key":"2829_CR24","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/mp.2016.3","volume":"21","author":"DR Goldsmith","year":"2016","unstructured":"Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696\u2013709.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"2829_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","volume":"71","author":"MB Howren","year":"2009","unstructured":"Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171\u201386.","journal-title":"Psychosom Med"},{"key":"2829_CR26","doi-asserted-by":"crossref","unstructured":"Dahl J, Ormstad H, Aass HCD et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology. 2014;45:77\u201386.","DOI":"10.1016\/j.psyneuen.2014.03.019"},{"issue":"3","key":"2829_CR27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jad.2011.08.003","volume":"139","author":"Y Liu","year":"2012","unstructured":"Liu Y, Ho RCM, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. 2012;139(3):230\u20139.","journal-title":"J Affect Disord"},{"key":"2829_CR28","doi-asserted-by":"crossref","unstructured":"Setiawan E, Wilson AA, Mizrahi R et al. Role of Translocator protein density, a marker of Neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015;72(3):268\u201375.","DOI":"10.1001\/jamapsychiatry.2014.2427"},{"issue":"3","key":"2829_CR29","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jad.2013.06.004","volume":"150","author":"V Valkanova","year":"2013","unstructured":"Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord. 2013;150(3):736\u201344.","journal-title":"J Affect Disord"},{"key":"2829_CR30","doi-asserted-by":"crossref","unstructured":"Kohler-Forsberg O, Buttenschon HN, Tansey KE et al. Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain Behav Immun. 2017;62:344\u201350.","DOI":"10.1016\/j.bbi.2017.02.020"},{"key":"2829_CR31","doi-asserted-by":"crossref","unstructured":"Hope S, Ueland T, Steen NE et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res. 2013;145(1\u20133):36\u201342.","DOI":"10.1016\/j.schres.2012.12.023"},{"key":"2829_CR32","doi-asserted-by":"crossref","unstructured":"Kohler O, Petersen L, Mors O et al. Infections and exposure to anti-infective agents and the risk of severe mental disorders: a nationwide study. Acta Psychiatr Scand. 2017;135(2):97\u2013105.","DOI":"10.1111\/acps.12671"},{"key":"2829_CR33","doi-asserted-by":"crossref","unstructured":"Krogh J, Benros ME, Jorgensen MB et al. The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun. 2014;35:70\u20136.","DOI":"10.1016\/j.bbi.2013.08.014"},{"key":"2829_CR34","doi-asserted-by":"crossref","unstructured":"Raison CL, Rutherford RE, Woolwine BJ et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression. JAMA Psychiatry. 2013;70(1):31\u201341.","DOI":"10.1001\/2013.jamapsychiatry.4"},{"key":"2829_CR35","doi-asserted-by":"crossref","unstructured":"Kappelmann N, Lewis G, Dantzer R et al. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018;23(2):335\u201343.","DOI":"10.1038\/mp.2016.167"},{"issue":"5","key":"2829_CR36","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1001\/jamapsychiatry.2014.3128","volume":"72","author":"HA Eyre","year":"2015","unstructured":"Eyre HA, Baune BT. Anti-inflammatory intervention in depression. JAMA Psychiatry. 2015;72(5):511.","journal-title":"JAMA Psychiatry"},{"key":"2829_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pnpbp.2014.06.011","volume":"54","author":"HA Eyre","year":"2014","unstructured":"Eyre HA, Stuart MJ, Baune BT. A phase-specific neuroimmune model of clinical depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;54:265\u201374.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2829_CR38","doi-asserted-by":"crossref","unstructured":"Eyre HA, Air T, Proctor S et al. A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2015;57:11\u20136.","DOI":"10.1016\/j.pnpbp.2014.10.003"},{"key":"2829_CR39","doi-asserted-by":"crossref","unstructured":"Malhi GS, Bassett D, Boyce D et al. Royal Australian and new Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087\u2013206.","DOI":"10.1177\/0004867415617657"},{"key":"2829_CR40","doi-asserted-by":"crossref","unstructured":"McIntyre RS, Harrison J, Loft H et al. The effects of Vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016 Oct; 19(10): pyw055.","DOI":"10.1093\/ijnp\/pyw055"},{"key":"2829_CR41","doi-asserted-by":"crossref","unstructured":"Kohler O, Benros ME, Nordentoft M et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381\u201391.","DOI":"10.1001\/jamapsychiatry.2014.1611"},{"key":"2829_CR42","doi-asserted-by":"crossref","unstructured":"Na KS, Lee KJ, Lee JS et al. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:79\u201385.","DOI":"10.1016\/j.pnpbp.2013.09.006"},{"key":"2829_CR43","doi-asserted-by":"crossref","unstructured":"Chen G, Lee R, Hojer AM et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727\u201336.","DOI":"10.1007\/s40261-013-0117-6"},{"key":"2829_CR44","doi-asserted-by":"crossref","unstructured":"Areberg J, Petersen KB, Chen G et al. Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic Clin Pharmacol Toxicol. 2014;115(6):552\u20139.","DOI":"10.1111\/bcpt.12256"},{"key":"2829_CR45","doi-asserted-by":"crossref","unstructured":"Abbasi SH, Hosseini F, Modabbernia A et al. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord. 2012;141(2\u20133):308\u201314.","DOI":"10.1016\/j.jad.2012.03.033"},{"key":"2829_CR46","doi-asserted-by":"crossref","unstructured":"Akhondzadeh S, Jafari S, Raisi F et al. Clinical trial of adjunctive CELECOXIB treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26(7):607\u201311.","DOI":"10.1002\/da.20589"},{"key":"2829_CR47","doi-asserted-by":"crossref","unstructured":"Muller N, Schwarz MJ, Dehning S et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680\u20134.","DOI":"10.1038\/sj.mp.4001805"},{"key":"2829_CR48","unstructured":"Majd M, Hashemian F, Hosseini SM et al. A randomized, double-blind, placebo-controlled trial of Celecoxib augmentation of sertraline in treatment of drug-naive depressed women: a pilot study. Iran J Pharm Res. 2015;14(3):891\u20139."},{"key":"2829_CR49","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Br J Psychiatry"},{"key":"2829_CR50","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fpsyt.2016.00150","volume":"7","author":"BT Baune","year":"2016","unstructured":"Baune BT, Air T. Clinical, functional, and biological correlates of cognitive dimensions in major depressive disorder - rationale, design, and characteristics of the cognitive function and mood study (CoFaM-study). Front Psychiatry. 2016;7:150.","journal-title":"Front Psychiatry"},{"key":"2829_CR51","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22\u201333. quiz 34\u201357"},{"key":"2829_CR52","doi-asserted-by":"crossref","unstructured":"Interian A, Chesin M, Kline A et al. Use of the Columbia-Suicide Severity Rating Scale (C-SSRS) to classify suicidal behaviors. Arch Suicide Res. 2018;22(2):278\u201394.","DOI":"10.1080\/13811118.2017.1334610"},{"issue":"Pt 4","key":"2829_CR53","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.2044-8260.1996.tb01212.x","volume":"35","author":"D Mockler","year":"1996","unstructured":"Mockler D, Riordan J, Sharma T. A comparison of the NART (restandardized) and the NART-R (revised). Br J Clin Psychol. 1996;35(Pt 4):567\u201372.","journal-title":"Br J Clin Psychol"},{"issue":"7","key":"2829_CR54","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"key":"2829_CR55","doi-asserted-by":"crossref","unstructured":"Rosa AR, Sanchez-Moreno J, Martinez-Aran A et al. Validity and reliability of the functioning assessment short test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3:5.","DOI":"10.1186\/1745-0179-3-5"},{"key":"2829_CR56","doi-asserted-by":"crossref","unstructured":"Krieger T, Zimmermann J, Huffziger S et al. Measuring depression with a well-being index: further evidence for the validity of the WHO well-being index (WHO-5) as a measure of the severity of depression. J Affect Disord. 2014;156:240\u20134.","DOI":"10.1016\/j.jad.2013.12.015"},{"key":"2829_CR57","doi-asserted-by":"crossref","unstructured":"Despiegel N, Danchenko N, Francois C et al. The use and performance of productivity scales to evaluate presenteeism in mood disorders. Value Health. 2012;15(8):1148\u201361.","DOI":"10.1016\/j.jval.2012.08.2206"},{"key":"2829_CR58","doi-asserted-by":"crossref","unstructured":"McIntyre RS, Harrison J, Loft H et al. The THINC-integrated tool (THINC-it) screening assessment for cognitive dysfunction: validation in patients with major depressive disorder. J Clin Psychiatry. 2017;78(7):873\u201381.","DOI":"10.4088\/JCP.16m11329"},{"key":"2829_CR59","doi-asserted-by":"crossref","unstructured":"Lanas A, Goldstein JL, Chan FK et al. Risk factors associated with a decrease >\/=2 g\/dL in haemoglobin and\/or >\/=10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR). Aliment Pharmacol Ther. 2012;36(5):485\u201392.","DOI":"10.1111\/j.1365-2036.2012.05213.x"},{"key":"2829_CR60","doi-asserted-by":"crossref","unstructured":"Tomizawa M, Shinozaki F, Hasegawa R et al. Low hemoglobin levels are associated with upper gastrointestinal bleeding. Biomed Rep. 2016;5(3):349\u201352.","DOI":"10.3892\/br.2016.727"},{"key":"2829_CR61","doi-asserted-by":"crossref","unstructured":"Hooper R, Forbes A, Hemming K et al. Analysis of cluster randomised trials with an assessment of outcome at baseline. BMJ. 2018;360:k1121.","DOI":"10.1136\/bmj.k1121"},{"key":"2829_CR62","doi-asserted-by":"crossref","unstructured":"Eyre HA, Air T, Pradhan A et al. A meta-analysis of chemokines in major depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;68:1\u20138.","DOI":"10.1016\/j.pnpbp.2016.02.006"},{"key":"2829_CR63","doi-asserted-by":"crossref","unstructured":"Udina M, Moreno-Espana J, Capuron L et al. Cytokine-induced depression: current status and novel targets for depression therapy. CNS Neurol Disord Drug Targets. 2014;13(6):1066\u201374.","DOI":"10.2174\/1871527313666140612121921"},{"key":"2829_CR64","doi-asserted-by":"crossref","unstructured":"Dantzer R, O'Connor JC, Freund GG et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46\u201356.","DOI":"10.1038\/nrn2297"},{"key":"2829_CR65","doi-asserted-by":"crossref","unstructured":"Dantzer R, O'Connor JC, Lawson MA et al. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011;36(3):426\u201336.","DOI":"10.1016\/j.psyneuen.2010.09.012"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2829-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2829-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2829-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T23:10:19Z","timestamp":1566256219000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2829-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2829"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2829-7","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,20]]},"assertion":[{"value":"16 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Royal Adelaide Hospital Human Research Ethics Committee (reference number R20170320 HREC\/17\/RAH\/111). Study participants have all study details explained to them in writing and in person before giving informed consent.The present trial is conducted in full cooperation with the World Health Organization\u2019s International Standards for Clinical Trial Registries.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"447"}}